DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key
word(s): Half Year Results/Forecast
Record quarter despite restructuring expenses
04.08.2015 / 07:45
---------------------------------------------------------------------
Press release
Record quarter despite restructuring expenses
Berlin, August 4, 2015. Berlin-based Eckert & Ziegler Strahlen- und
Medizintechnik AG (ISIN DE0005659700), a specialist for isotope technology
applications in medicine, science and industry, recorded one of its
most-successful quarters ever in spite of considerable provisions being set
aside for risk provisioning and the restructuring of ailing business units.
The company's quarterly sales exceeded the EUR 35.0 million mark for the
first time, and income after tax leapt to EUR 4.8 million following the
sale of its interest in OctreoPharm Sciences GmbH.
In the first half of 2015 sales increased by EUR 7.1 million, or 11 %, to
EUR 69.0 million. A majority of this amount, EUR 6.0 million, is due to the
more favorable US dollar/euro exchange rate. EBIT almost doubled year on
year to EUR 11.7 million. Profit for the first half of the year after taxes
and minority interests increased by more than 100 % to EUR 7.5 million, or
EUR 1.41 per share.
The Isotope Products segment benefited the most from the weak euro, while
also recording a positive acquisition effect. Sales increased by 17 % to
EUR 33.6 million. However, these effects did not result in any increase in
profit, meaning that EBIT remained constant at EUR 7.1 million.
Sales in the Radiation Therapy segment increased by EUR 0.8 million due to
currency effects to EUR 14.7 million, but were not enough to cover the cost
base. Operating EBIT amounted to EUR -1.4 million. There were also positive
currency effects of EUR 0.8 million and provisions of EUR 1.3 million for
agreed restructuring measures and site closures. Segment EBIT therefore
came in at EUR -1.9 million.
The sales of the Radiopharma segment rose by not only the currency effect
but also organically, especially in the equipment division and with the
gallium generators. The "Other operating income" item includes most of the
proceeds arising from the sale of the OctreoPharm investment. As a result,
EBIT increased many times over to EUR 7.4 million.
Price increases meant that the Others segment registered a slight increase
in sales of EUR 0.1 million to EUR 3.5 million. EBIT increased
significantly by EUR 0.6 million to EUR -0.8 million. The change is
predominately due to the balance of a positive and a negative effect: The
segment also received proceeds from the sale of the OctreoPharm investment.
The segment was also impacted by a price increase announced in an important
disposal channel, thereby further increasing provisions for waste material.
Cash flow from operating activities was up considerably year on year and
achieved EUR 3.9 million, mainly due to the decrease in the Radiation
Therapy segment's receivables.
For the fiscal year 2015, sales are expected to rise to over EUR 133
million, while an improvement in earnings to over EUR 2.00 per share is
also being targeted.
The complete quarterly financial statements can be viewed under:
http://www.ezag.com/fileadmin/ezag/user-uploads/pdf/financial-reports/engl
isch/euz215e.pdf
About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), with
approximately 700 employees, is one the world's largest providers of
isotope technology for radiation therapy and nuclear medicine.
Contributing to saving lives.
For further information or questions, please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations Robert-Rössle-Str.
10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com
---------------------------------------------------------------------
04.08.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Eckert & Ziegler Strahlenund Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulated Market in Frankfurt (Prime Standard), Stuttgart;
Regulated Unofficial Market in Berlin, Dusseldorf,
Hamburg, Munich
End of News DGAP News-Service
---------------------------------------------------------------------
383253 04.08.2015
DGAP-News: Record quarter despite restructuring expenses
| Source: EQS Group AG